Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

C- and N-terminal Epitope Conjugate immune Cell Targeted Vaccines

Objective

CNECT-VAX will validate the technical and commercial feasibility of a new cancer vaccine platform that uses nanobodies targeting dendritic cells to co-deliver antigens in vivo. As of 2019, cancer affects over 19 million people worldwide and results in almost 10 million death annually, however, the treatment of patients remains a challenge. Immunotherapy options including dendritic cell (DC) based vaccines have become available, but the clinical efficacy of such treatment remains very modest and restricted to patient subsets. To overcome the limitations in the current state-of-art solutions and break barriers to achieve higher clinical efficacy, Dr. Martijn Verdoes proposes a novel molecular vaccine strategy that effectively delivers target antigens to DCs in vivo in the patient to concomitantly induce robust synergistic CD4+ and CD8+ T cell responses.
The technical feasibility of CNECT-VAX will be assessed both in vitro and in vivo, using monocyte-derived human dendritic cells (MoDC) and a mouse model containing humanized DCs respectively. In both systems, the functionality of DCs and the consequent T cell activation and immune responses will be measured. Subsequently, commercial feasibility will be determined by verifying IP position and strategy, performing in-depth market and competitor analyses, and finally consolidating these into a business plan to establish the best path to commercialization. Successful commercialization of CNECT-VAX could reduce the profound socioeconomic burden of cancer, extend and improve the lives of patients, provide the pharmaceutical industry with further collaborative opportunities, and stimulate further scientific research based on this platform to treat other pathogenic diseases.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2022-POC1

See all projects funded under this call

Host institution

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 150 000,00
Address
GEERT GROOTEPLEIN 10 ZUID
6525 GA NIJMEGEN
Netherlands

See on map

Region
Oost-Nederland Gelderland Arnhem/Nijmegen
Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Beneficiaries (1)

My booklet 0 0